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Abstract
Objective To evaluate the inﬂuence of comorbid cardio-
vascular disease severity on health-related quality of life
(HRQL) in men treated with radical prostatectomy (RP) or
radiotherapy (RT) for early stage prostate cancer.
Methods Subjects (n = 830) with non-metastatic disease
who had been diagnosed in 2000–2002 were drawn from
CanceroftheProstateStrategicUrologicResearchEndeavor
(CaPSURE). We evaluated the inﬂuence of cardiovascular
disease (CVD) severity on generic and disease-speciﬁc
HRQL before and 6, 12, 18, and 24 months after treatment
with RP or RT. HRQL was measured with the SF-36 and the
UCLA Prostate Cancer Index.
Results Men with moderate (n = 193) or severe (n = 51)
cardiovascular disease had worse pre-treatment HRQL than
did men without CVD (n = 293) (P\0.01); HRQL scores
were worse in men referred for RT. During 24 months of
follow-up, men with moderate or severe CVD had worse
SF-36 physical and mental component summaries and
worse bowel function at all time points (P\0.05). Men
with severe CVD also experienced a slower recovery in
physical function (P = 0.03) and sexual functioning
(P = 0.02) than did men without CVD.
Conclusions Prostate cancer patients with moderate to
severe CVD have worse HRQL during follow-up. Those
with severe CVD recover their physical and sexual func-
tioning more slowly after treatment.
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Because most men are older at the time of diagnosis with
prostate cancer [1], many have comorbid medical condi-
tions. Hence, cancer treatment decisions are made in the
context of an older individual’s pre-existing comorbidity in
order to provide high quality cancer care. In 2001 the
National Institute on Aging (NIA) and the National Cancer
Institute (NCI) recognized this and issued recommenda-
tions for studies on comorbidity and cancer in older
patients [2]. Since then, comorbidity in prostate cancer has
been studied in relation to treatment [3–6], early compli-
cations after radical prostatectomy [7], and overall survival
[5–7], providing valuable new insights into the importance
of comorbidity when considering treatment and prognosis
in older prostate cancer patients. Unfortunately, most of
these studies assessed comorbidity with a checklist as
being present or absent, or incorporated a simple count of
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Also, these studies focused on major comorbid conditions,
such as diabetes, heart disease or gastrointestinal problems,
whereas more common problems, such as hypertension, that
can affect daily activity ought to be included as well [2].
Because the majority of men with prostate cancer do not
die of it [8], accurate assessment of comorbid conditions
can inform treatment decisions. However, the impact of
comorbidity on health-related quality of life (HRQL) in
prostate cancer patients has rarely been reported [9–11] and
is among the factors often not well-described in HRQL
outcomes studies [12]. A previous CaPSURE analysis
showed that men with heart disease showed a greater
worsening in their physical functioning after radical pro-
statectomy [9], whereas a study among prostate cancer
patients treated with radiotherapy revealed gastro-intestinal
complications associated with the prevalence of diabetes
[13]. Both studies suggest that there could be an interaction
among co-morbidity, prostate cancer treatment, and
HRQL.
Our objective was to evaluate the inﬂuence of comorbid
cardiovascular disease on HRQL in men treated with rad-
ical prostatectomy or radiotherapy for early stage prostate
cancer. Cardiovascular disease (CVD), the most prevalent
comorbid condition in prostate cancer patients [5], ranges
broadly in severity from controlled hypertension to myo-
cardial infarction or congestive heart failure. To assess
CVD severity, we used the validated Total Illness Burden
Index for Prostate Cancer (TIBI-CaP) [14], a patient-
reported measure of comorbidity speciﬁcally developed for
the assessment of severity of concurrent disease in prostate
cancer patients. We evaluated the inﬂuence of CVD on
generic and disease-speciﬁc HRQL before and 6, 12, 18,
and 24 months after treatment for patients with no, mild,
moderate, or severe CVD according to type of treatment.
We hypothesized that increasing severity of CVD would be
associated with worse baseline generic and disease-speciﬁc
HRQL and slower recovery of HRQL during 24 months of
follow-up.
Methods
Patients
The study sample was drawn from Cancer of the Prostate
Strategic Urologic Research Endeavor (CaPSURE), a lon-
gitudinal,observationalregistryofmenwithprostatecancer.
Data are collected from participant questionnaires and
medical records at 34 community-based practices, 3 aca-
demicand3VeteransAdministrationclinicalsitesacrossthe
US. Clinical data (medical history, tumor stage, prostate-
speciﬁc antigen [PSA], and treatment) are provided by the
urologist or radiation oncologist at clinical encounters.
Subjects report HRQL data at entry and semiannually until
death orwithdrawal fromthe study. Additionaldetails of the
project methods have been previously reported [15]. In
additiontothesemiannualquestionnaires,attheendof2002
the Total Illness Burden Index for Prostate Cancer (TIBI-
CaP) was sent to 4,635 active CaPSURE participants, of
whom 3,409 (74%) returned the questionnaire [14].
For this analysis, we included all subjects diagnosed in
2000–2002 with non-metastatic disease (clinical stage
T1–T3) and who underwent radical prostatectomy (RP) or
radiation therapy (RT; external beam or brachytherapy).
All subjects completed questionnaires pretreatment and at
least twice within 24 months after treatment. All subjects
completed the TIBI-CaP within the same 24 months after
treatment. The ﬁnal analysis included 830 men, of whom
78 had 2, 216 had 3, and 536 had 4 post-treatment ques-
tionnaires, yielding 3,778 questionnaires.
Measures
Risk of prostate cancer recurrence
Subjects were stratiﬁed according to pre-treatment risk
using a modiﬁcation of the D’Amico risk classiﬁcation
[16], namely high (PSA greater than 20 ng/ml, Gleason
sum greater than 7, primary Gleason pattern 4 or 5, or
clinical stage T3a), intermediate (PSA 10.1–20 ng/ml,
Gleason sum 7, secondary Gleason pattern 4 or 5, or
clinical stage T2b/c), or low (PSA 10 ng/ml or less,
Gleason sum less than 7 without pattern 4 or 5, and clinical
stage T1 or T2a).
Comorbidity
The TIBI-CaP [14], a patient-reported measure of comor-
bidity, was used to measure the presence and severity of
comorbid conditions. The developers of the TIBI-CaP
modiﬁed the original TIBI [17] based on a pilot study [18]
and then established its validity in 2,894 CaPSURE par-
ticipants by showing that it accurately predicted both
mortality and future quality of life [14]. The TIBI-CaP
includes 84 items in 11 sub-dimensions: pulmonary disease
and congestive heart failure, heart disease (heart attack,
coronary artery bypass, coronary angioplasty), stroke and
neurologic disease, gastrointestinal conditions, other can-
cers (excluding prostate), arthritis, foot and leg conditions,
eye and vision conditions, hearing problems, hypertension,
and diabetes. Using a scoring algorithm that assigns points
based on severity of illness, scores are derived for each of
the 11 sub-dimensions, with higher scores corresponding to
greater severity of comorbidities.
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123We combined three sub-domains—congestive heart
failure (CHF), atherosclerotic heart disease (ASHD), and
hypertension—into one cardiovascular disease severity
score. In accordance with the TIBI-CaP scoring system, we
weighted the sub-dimensions differentially. ASHD and
CHF, both considered to have the greatest clinical impact
on illness burden, were stratiﬁed based on clinical judg-
ment into four severity levels (0–3 points), whereas
hypertension, considered to have the least impact, was
stratiﬁed in two severity levels (no or controlled vs
uncontrolled hypertension). The severity weights for each
sub-dimension were summed to create a TIBI-CVD score,
which could range from 0 to 7. Scores in our sample ranged
from 0 to 7 with a mean of 1.2 (standard deviation, 1.3) and
a median of 1. For example, an individual with angina or
previous myocardial infarction without current complaints
earned one point, but if he reported chest pain at rest, he
earned three ASHD points. Or, a subject who reported
shortness of breath at rest all the time in the presence of
swollen ankles most of the day earned three CHF points.
Based on clinical judgment and after comparing the base-
line RAND 36 domains most closely related to chronic
disease severity (physical functioning and role limita-
tions—physical) as an indicator of general health status, the
TIBI-CVD score was stratiﬁed as no CVD (0 points), mild
CVD (1 point), moderate CVD (2–3 points), and severe
CVD (4–7 points).
Health-related quality of life
We measured general HRQL with the RAND 36-Item
Health Survey, version 1.0, a 36-item questionnaire that
quantiﬁes general physical and mental HRQOL [19]. In
this analysis, we examined the domains of physical func-
tion, general health, bodily pain, vitality, social
functioning, mental health, role-physical (limitations due to
physical problems), role-emotional (limitations due to
emotional problems), and the physical and mental com-
ponent summary scores. Differences between subgroups of
at least 0.5 SD were considered clinically meaningful. We
measured disease-speciﬁc HRQL with the UCLA Prostate
Cancer Index (PCI) [20]. This self-administered, 20-item
questionnaire quantiﬁes prostate cancer-speciﬁc HRQL in
six domains, including urinary, bowel, and sexual function
and bother. We examined only function (urinary, sexual,
and bowel function) and not bother. All PCI outcomes are
scored so that higher values indicate better quality of life.
Statistical analysis
We compared baseline demographic and clinical vari-
ables across TIBI-CVD severity level with ANOVA for
continuous variables and chi-square analyses for cate-
gorical variables. We carried out linear regression
analyses to evaluate the association between baseline
demographic and clinical characteristics and HRQL.
Variables were included in the analysis of covariance
(ANCOVA) if they showed a univariate association
(P\0.05) with HRQL outcomes.
From longitudinal studies, it is well known that most
subjects report a decline in HRQL right after treatment and
then experience a gradual improvement, resulting in a
negative and positive regression slope when evaluating
HRQL from baseline to 24 months. In order to understand
the process of HRQL decline after treatment and then
recovery after a while, we separately analyzed the decline
of HRQL and then recovery. These separate analyses also
resulted in better ﬁtting models.
We used ANCOVA to compare mean baseline and
change in HRQL scores within the ﬁrst 6 months across
levels of TIBI-CVD severity. Covariates were selected
based on prior knowledge and previous CaPSURE analyses
on comorbidity and HRQL [9, 11]. In addition, we incor-
porated baseline HRQL scores as a covariate for quality of
life in all models, as they are known to correlate strongly
with outcomes over time [21, 22]. All of these variables
appeared to be independently associated (P\0.05) with
HRQL.
We used repeated measures analyses with mixed mod-
eling to examine changes in HRQL between 6 and
24 months after diagnosis. Repeated measures analysis
takes into account the correlation of repeated outcomes
among subjects and handles missing values in an optimal
way by accounting for the time patterns of the available
data. We evaluated the positive regression slope, assessing
HRQL at 6, 12, 18, and 24 months, but incorporated
baseline HRQL scores as a covariate for quality of life in
all models, as they are known to correlate strongly with
outcomes over time [21, 22]. Covariates were selected
based on prior knowledge and previous CaPSURE analyses
on comorbidity and HRQL [9, 11]. All of these variables
appeared to be independently associated (P\0.05) with
HRQL. We also tested interaction terms for CVD severity
and time and CVD severity and treatment to evaluate
whether CVD severity had a different effect on HRQL over
time or for different therapies.
As comorbidity has been associated with less aggressive
treatment [3–6], and a previous CaPSURE analysis
revealed that men with CVD were more likely to be treated
with radiotherapy than prostatectomy, we separately ana-
lyzed baseline and follow-up HRQL for the two treatments.
We used P\0.05 to report statistical signiﬁcance and
made no formal adjustment for multiple testing. All
statistical analyses were performed in SAS 9.1 (SAS
Institute Inc., Cary, NC).
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123Table 1 Demographic and medical characteristics for prostate cancer patients according to their TIBI-CaP cardiovascular disease severity score
Characteristic TIBI-CaP cardiovascular disease severity
No (n = 293) Mild (n = 293) Moderate (n = 193) Severe (n = 51) P-value
Age (mean years) 63.7 ± 7.8 64.9 ± 7.8 66.9 ± 7.3 67.2 ± 7.1 \0.0001
Ethnicity
White (%) 273 (93) 276 (94) 187 (97) 45 (88) 0.10
Partner status
a (%)
Partnered 265 (91) 271 (93) 175 (92) 43 (84) 0.24
Education level
b (%)
Less than high school 108 (38) 95 (33) 79 (42) 25 (51) 0.06
High school graduate 45 (16) 59 (20) 39 (21) 12 (24)
Some college 50 (17) 51 (18) 28 (15) 6 (12)
College graduate 84 (29) 84 (29) 41 (22) 6 (12)
Income
c (%)
\30,000 68 (27) 58 (21) 51 (29) 17 (34) 0.06
30–50,000 65 (25) 72 (27) 47 (27) 17 (34)
50–70,000 48 (19) 51 (19) 40 (23) 4 (8)
[75,000 75 (29) 89 (33) 35 (20) 12 (24)
Insurance (%)
Medicare supplement 86 (30) 96 (33) 70 (36) 20 (39) 0.13
Medicare 36 (12) 33 (11) 35 (18) 9 (18)
Private insurance 149 (51) 144 (49) 73 (38) 18 (35)
Other/none 22 (8) 20 (7) 15 (8) 4 (8)
PSA (ng/ml) at diagnosis
Mean ± SD 8.0 ± 8.3 6.8 ± 5.4 8.2 ± 8.2 7.6 ± 6.2 0.10
Median 6.0 5.5 6.2 5.6
Biopsy Gleason score
Mean ± SD 6.3 ± 0.7 6.3 ± 0.8 6.5 ± 0.8 6.4 ± 0.7 0.16
Median 6.0 6.0
Tumor stage (%)
1 158 (54) 153 (52) 103 (53) 26 (51) 0.73
2 129 (44) 138 (47) 88 (46) 25 (49)
3 6 (2) 2 (1) 2 (1) 0
Recurrence risk at diagnosis
d
Low 128 (45) 145 (50) 79 (42) 20 (40) 0.10
Intermediate 118 (41) 90 (31) 69 (36) 20 (40)
High 41 (14) 53 (18) 42 (22) 10 (20)
CAPRA score
Mean ± SD 2.6 ± 1.6 2.4 ± 1.6 2.8 ± 1.7 2.8 ± 2.0 0.11
Median 2.0 2.0 2.0 2.5
Treatment
RP 198 (68) 189 (65) 99 (51) 23 (45) 0.002
Brachy ± EBRT 60 (20) 68 (23) 66 (34) 19 (37)
EBRT 35 (12) 36 (12) 28 (15) 9 (18)
BMI (kg/m
2)
e
\25.0 79 (28) 68 (24) 36 (19) 7 (15) 0.006
25.0–29.9 160 (57) 168 (58) 101 (55) 24 (50)
C30 44 (16) 53 (18) 48 (26) 17 (35)
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123Results
Of the 830 men who met the inclusion criteria, 293 (35%)
reported no CVD, while 293 (35%) were categorized with
mild CVD, 193 (23%) with moderate CVD, and 51 (6%)
with severe CVD. Men with increasing severity of CVD
were older, more likely to be treated with brachytherapy or
external beam radiation therapy, more likely to be over-
weight, and more likely to report comorbidities other than
CVD. Men with moderate or severe CVD were more likely
to have less education and lower household income
(Table 1).
Baseline generic and disease-speciﬁc HRQL was nega-
tively associated with increasing CVD severity (raw means
are presented in Table 2). Men with mild CVD had only
slightly lower HRQL scores that were clinically and sta-
tistically similar to men without CVD. Men with moderate
CVD scored worse on the physical, vitality, and general
Table 1 continued
Characteristic TIBI-CaP cardiovascular disease severity
No (n = 293) Mild (n = 293) Moderate (n = 193) Severe (n = 51) P-value
TIBI-CaP score without CVD
f
0–2 202 (78) 206 (76) 105 (63) 18 (45) \0.0001
3–5 55 (21) 57 (21) 54 (32) 10 (25)
6–9 3 (1) 7 (3) 9 (5) 12 (30)
RP = Radical prostatectomy; EBRT = external beam radiotherapy
a Partner status is missing for seven subjects
b Education level is missing for 18 subjects
c Income is missing for 81 subjects
d Based on modiﬁcation of the nomograms of D’Amico [16] missing for 15 subjects
e BMI is missing for 25 subjects
f TIBI-CaP score without CVD is missing for 92 subjects
Table 2 Health-related quality of life (raw means) for prostate cancer patients before treatment according to their TIBI-CaP cardiovascular
disease severity
Variable TIBI-CaP cardiovascular disease severity
No (n = 293) Mild (n = 293) Moderate (n = 193) Severe (n = 51) P-value
a
SF-36 generic HRQL Means ± SD Means ± SD Means ± SD Means ± SD
Physical function 93 ± 13 91 ± 14 79 ± 21** 68 ± 27** \0.0001
Role physical 91 ± 24 88 ± 27 66 ± 40** 57 ± 42** \0.0001
Role emotional 89 ± 27 89 ± 26 80 ± 34* 67 ± 39** \0.0001
Vitality 75 ± 16 72 ± 16 61 ± 19** 52 ± 20** \0.0001
Mental health 81 ± 15 82 ± 14 77 ± 16* 73 ± 16* 0.02
Social function 92 ± 16 92 ± 16 84 ± 22** 80 ± 24* 0.0001
Bodily pain 90 ± 15 88 ± 18 78 ± 23** 71 ± 25** \0.0001
General health 80 ± 16 78 ± 16 65 ± 20** 55 ± 23** \0.0001
Mental component score 53 ± 85 4 ± 75 1 ± 10* 49 ± 10* 0.004
Physical component score 54 ± 65 3 ± 74 7 ± 10** 43 ± 12** \0.0001
UCLA prostate cancer index
Urinary function 95 ± 11 93 ± 11 91 ± 14** 86 ± 14* 0.009
Sexual function 60 ± 28 54 ± 30 46 ± 31 33 ± 30** 0.005
Bowel function 90 ± 13 91 ± 11 85 ± 15** 80 ± 18* 0.0001
a P-values calculated for the independent effect of CVD severity, adjusted for age, race, educational level, partner status, income, BMI,
treatment, and number of comorbidities other than CVD
*HRQL score statistically signiﬁcantly different from men without CVD at the P\0.05 level
**HRQL score statistically signiﬁcantly different from men without CVD at the P\0.001 level
Qual Life Res (2008) 17:845–855 849
123health domains of the SF-36. Men with severe CVD had
worse generic and disease-speciﬁc HRQL than those
without CVD.
Separate baseline analyses for men treated with RP or
RT both revealed similar patterns of raw HRQL scores that
worsened with increasing CVD severity, although some
HRQL scale scores were lower for men treated with RT
(Table 3). Direct comparison between both treatment
groups showed statistically signiﬁcant worse raw scores for
the physical component summary score and sexual func-
tioning among men treated with RT for all subgroups of
CVD severity. However, these differences disappeared
after adjustment for confounding variables (data not
shown). Among men with severe CVD (TIBI-CVD score
4–7), those treated with RP had a mean TIBI-CVD score of
4.1 (SD = 0.5), while those treated with RT had a mean
Table 3 Health-related quality of life for prostate cancer patients before treatment and changes within 6-month follow-up according to their
TIBI-CaP cardiovascular disease severity
Radical prostatectomy TIBI-CaP cardiovascular disease severity
No (n = 159) Mild (n = 159) Moderate (n = 84) Severe (n = 22) P-value
a,b
Means ± SD Means ± SD Means ± SD Means ± SD
Mental component score
Before treatment 53 ± 95 4 ± 85 1 ± 10 50 ± 11 0.04
Change within 6 months 1 ± 90 ± 70 ± 8 -1 ± 7 0.55
Physical component score
Before treatment 55 ± 65 4 ± 64 8 ± 10 48 ± 10 \0.0001
Change within 6 months -4 ± 9 -3 ± 8 -1 ± 9 -1 ± 8 0.67
Urinary function
Before treatment 95 ± 11 94 ± 11 91 ± 14 86 ± 13 0.08
Change within 6 months -31 ± 27 -31 ± 28 -27 ± 28 -25 ± 29 0.31
Sexual function
Before treatment 64 ± 26 60 ± 28 53 ± 29 47 ± 30 0.10
Change within 6 months -40 ± 27 -41 ± 25 -37 ± 27 -34 ± 24 0.39
Bowel function
Before treatment 90 ± 14 92 ± 10 85 ± 14 81 ± 15 0.0001
Change within 6 months -1 ± 14 -4 ± 13 -1 ± 17 -3 ± 19 0.28
Radiotherapy
c No (n = 78) Mild (n = 94) Moderate (n = 85) Severe (n = 22)
Mental component score
Before treatment 54 ± 75 4 ± 85 2 ± 10 48 ± 10 0.24
Change within 6 months 0 ± 60 ± 7 -2 ± 10 3 ± 8 0.58
Physical component score
Before treatment 53 ± 65 1 ± 94 5 ± 10 39 ± 11 \0.0001
Change within 6 months -3 ± 7 -2 ± 7 -2 ± 9 -3 ± 8 0.29
Urinary function
Before treatment 95 ± 11 92 ± 11 90 ± 14 85 ± 15 0.09
Change within 6 months -11 ± 17 -10 ± 15 -11 ± 19 -10 ± 13 0.86
Sexual function
Before treatment 50 ± 30 42 ± 31 39 ± 30 22 ± 24 0.18
Change within 6 months -18 ± 24 -18 ± 26 -14 ± 23 -3 ± 17 0.88
Bowel function
Before treatment 91 ± 11 89 ± 12 84 ± 15 79 ± 20 0.07
Change within 6 months -7 ± 22 -7 ± 16 -9 ± 20 -13 ± 17 0.09
a P-values calculated for the independent effect of CVD severity on HRQL before treatment were adjusted for age, race, educational level,
partner status, income, BMI, and number of comorbidities other than CVD
b P-values calculated for the independent effect of CVD severity on HRQL change within 6 months were adjusted for HRQL score before
treatment, age, race, educational level, partner status, income, BMI, and number of comorbidities other than CVD
c Radiotherapy: Brachytherapy or external beam radiotherapy
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123TIBI-CVD score of 4.6 (SD = 0.8), suggesting that within
the severe CVD subgroup, men treated with RT had even
more severe CVD.
The change (worsening) of generic and disease-speciﬁc
HRQL in the ﬁrst 6 months after treatment was indepen-
dent of CVD severity (Table 3; Figs. 1 and 2). Multivariate
analyses, controlling for the confounding effect of age,
race, educational level, partner status, income, BMI, and
comorbidities other than CVD, revealed no statistically
signiﬁcant effect of CVD on change in HRQL in the ﬁrst
6 months.
During follow-up from 6 months up to 24 months after
diagnosis, moderate or severe CVD was associated with
worse physical (PCS) and mental (MCS) component
summary scores and bowel function scores after adjustment
for the confounding effect of baseline HRQL, age, race,
education, partner status, income, BMI, treatment, and
TIBI-CaP score without CVD (Table 4; Figs. 1 and 2). The
differences in HRQL across CVD severity groups were
parallel over time for the MCS and urinary and bowel
function. However, for PCS and sexual function, we
observed a signiﬁcant negative interaction between CVD
severity and time, suggesting that recovery after treatment
was slower with increasing CVD severity. The interaction
between CVD severity and treatment was not signiﬁcant.
HRQL trends over time for PCS, MCS, urinary, sexual and
bowel function are provided in Figs. 1 and 2.
Discussion
This population-based analysis of 830 men treated with
radical prostatectomy or radiation therapy for prostate
cancer showed that men with moderate or severe cardio-
vascular disease had worse pre-treatment generic and
disease-speciﬁc HRQL than did men without CVD; scores
were even worse in men referred for RT. During 24 months
of follow-up, men with moderate or severe CVD had worse
absolute HRQL scores for the physical and mental sum-
mary scores of the SF-36 and for bowel function at all time
points. Men with severe CVD also experienced a slower
recovery in physical and sexual functioning than did men
without CVD. CVD appears to have the same detrimental
effect on recovery after surgery or radiation.
Treatment decisions made by prostate cancer patients
may be inﬂuenced by non-clinical factors, such as age,
comorbid diseases, or personal preferences. Our ﬁnding
that men with moderate or severe CVD were more likely to
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123be treated with radiotherapy has been reported previously
in the CaPSURE database [23] and is consistent with other
studies showing that comorbidity was associated with less-
aggressive treatment [3–6, 23]. We also found that within
the strata of CVD severity, men treated with radiation
tended to report worse HRQL at baseline than men who
had surgery, suggesting that not only comorbidity severity,
but also health status informs the consideration of treat-
ment options. It remains unclear, however, whether
comorbidity is also considered when anticipating long-term
HRQL outcomes for a patient. And although comorbidity
has often been incompletely described in HRQL outcome
studies [12], the importance of its role is recognized in the
delivery of quality care to elderly cancer patients [2, 24].
Self-reported comorbidity data has been shown to cor-
relate highly with medical records abstraction and to be
reproducible [25]. More speciﬁcally, results of the Prostate
Cancer Outcomes Study (PCOS) showed that men with a
relatively recent prostate cancer diagnosis are generally
able to provide highly reliable reports of their concomitant
health conditions [26]. Noteworthy was the positive cor-
relation between severity of comorbidity and reliability in
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123its reporting, which led PCOS investigators to conclude
that condition severity should be obtained to increase the
likelihood of obtaining reliable data. The recently validated
TIBI-CaP was developed to provide a clinically useful and
systematic method to assess non-cancer morbidity in men
with prostate cancer [14]. In contrast to most other
comorbidity measures, the TIBI-CaP includes the severity
of conditions and was uniquely developed for use with
prostate cancer as the index condition, as recommended by
the NIH working group [2]. The aggregation of severity
across conditions mitigates the potential for patients to
report just one condition [14]—incorporating severity in
comorbidity assessment improves validity of the data [26].
Our ﬁndings suggest that it is not simply the presence or
absence of CVD, but its severity, that inﬂuences recovery
afterprostatecancertreatment:menwithmoderatetosevere
CVD reported signiﬁcantly lower scores at baseline and
follow-up. Still, even in this predominantly non-minority,
afﬂuent cohort, 29% of men had moderate to severe CVD.
The prevalence of moderate to severe CVD is likely even
higherinotherprostatecancerpopulationsthatincludemore
minority men with lower socioeconomic status. Although
men with moderate CVD severity reported worse HRQL,
only those with severe CVD reported a signiﬁcantly slower
recovery in physical and sexual functioning.
Although we were able to evaluate the effect of CVD on
HRQL recovery in prostate cancer patients treated with RP
and RT, the most frequently used treatments for men with
localized prostate cancer [27], we did not include men
treated with androgen deprivation therapy. The use of
androgen deprivation with radiotherapy has become com-
mon, even in low-risk patients [28], but the interplay
between CVD and androgen deprivation deserves further
attention. A recent analysis of 1,372 men from three ran-
domized trials showed that the use of androgen deprivation
was associated with fatal myocardial infarction in men
65 years or older [29]. Although the mechanisms respon-
sible for this effect are unclear, the authors recommend that
men of advanced age considering RT and androgen
deprivation for prostate cancer should be undergo cardio-
vascular evaluation before initiation of therapy [29].
Our study has several limitations. Because subjects
completed the TIBI-CaP within 24 months of diagnosis, the
presence and/or severity of comorbidity may have changed
since baseline. However, because baseline HRQL scores
corresponded well with the increasing level of CVD
severity and differed in the expected direction by treatment
group, comorbidity misclassiﬁcation bias seems unlikely. In
addition, CaPSURE is an observational database that has
been designed to track longitudinal health outcomes for
patients with prostate cancer. Clinical sites have been
selected to represent a breadth of practice settings (managed
care, fee-for-service practices, university teaching hospi-
tals) [5]. Although geographic representation is spread
throughout all regions of the US, the sample is not as eth-
nically diverse as the overall population of US men with
prostate cancer [11]. The fact that we observed a low mean
TIBI-CVD score in our sample suggests that we evaluated a
relatively healthy population of prostate cancer patients. It
is therefore possible that we underestimated the prevalence
of prostate cancer patients with moderate to severe CVD.
One strength of this study is the use of baseline HRQL,
known to be a strong predictor of future outcomes [21, 22].
Furthermore, the analysis of HRQL data from four time
points after diagnosis was optimized with mixed modeling,
giving us an ability to observe changes in HRQL over the
course of disease.
In conclusion, the observations of our longitudinal
analyses suggest that prostate cancer patients with moder-
ate to severe CVD have worse HRQL during follow-up and
Table 4 Repeated measures analyses with mixed modeling evaluating the association between TIBI-CaP cardiovascular disease severity and
HRQL during 24 months after diagnosis, adjusted for confounding variables
Variable SF 36 UCLA prostate cancer index
PCS estimate
(SE)
MCS estimate
(SE)
Urinary function
estimate (SE)
Sexual function
estimate (SE)
Bowel function
estimate (SE)
TIBI-CaP CVD severity
a
No Reference Reference Reference Reference Reference
Mild -0.6 (0.4) -0.2 (0.7) -1.1 (1.6) -1.5 (1.6) -1.8 (0.8)
Moderate -1.7 (0.5)* -1.3 (0.6)* -0.5 (1.9) -0.6 (1.8) -3.8 (1.0)**
Severe -3.2 (0.8)** -3.7 (0.9)** -0.0 (3.1) -2.2 (3.0) -5.2 (1.6)*
Time* TIBI-CaP CVD severity (interaction)
a 0.03 NS NS 0.02 NS
Treatment* TIBI-CaP CVD severity (interaction)
a NS NS NS NS NS
a P-values calculated for the independent effect of CVD severity, adjusted for baseline HRQL, age, race, educational level, partner status,
income, BMI, treatment, number of comorbidities other than CVD
*HRQL score statistically signiﬁcantly different from men without CVD at the P\0.05 level
**HRQL score statistically signiﬁcantly different from men without CVD at the P\0.001 level
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123that men with severe CVD recover their physical and
sexual functioning more slowly after treatment. Although
men treated with radiation tended to have worse baseline
scores than men treated with surgery, CVD severity had the
same detrimental effect on HRQL during follow-up in both
groups. Because the prognosis in prostate cancer is gen-
erally good, men may wish to consider the expected impact
of comorbidity on long-term HRQL outcomes when
deciding on primary treatment. Future studies should also
examine the impact of long-term androgen ablation on
cardiovascular outcomes.
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